8
Participants
Start Date
December 14, 2022
Primary Completion Date
August 31, 2023
Study Completion Date
August 31, 2023
Aumolertinib monotherapy
Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.
Osimertinib monotherapy
80 mg tablet administered orally, once daily
Pemetrexed
Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy
Cisplatin
Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
Carboplatin
Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
Paclitaxel
Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.
Nab paclitaxel
Administered by IV Infusion given over 4 fixed cycles per prescribing information.
Gemcitabine
Administered by IV Infusion over 4 fixed cycles per prescribing information.
Memorial Cancer Institute, Hollywood
Memorial Cancer Institute, Pembroke Pines
SCRI - Tennessee Oncology- Nashville, Nashville
SCRI - Tennessee Oncology PLLC- Chattanooga, Chattanooga
QCCA - Mission Blood & Cancer, Des Moines
Highlands Oncology Group, Springdale
Northwest Medical Specialties, PLLC, Tacoma
Summit Health, Florham Park
Lead Sponsor
EQRx International, Inc.
INDUSTRY